

REMARKS

The Examiner has advanced a restriction requirement, requiring the Applicants to elect one of three groups of claims. The Examiner has grouped the claims as follows:

Group I: Claim 11.

Group II: Claim 12.

Group III: Claims 1, 3, 6-7, 10 and 14-18.

In response, Applicants elect without traverse the invention defined by Group III, which includes claims 1, 3, 6-7, 10 and 14-18. Such election is made without prejudice to the non-elected claims in any related patent applications.

With respect to the elected group III, the Examiner has further required election of a single disclosed specie of movement disorder. In response, the Applicants elect the movement disorder that comprises Parkinson's disease. This election is made without prejudice to any other non-elected movement disorders in any related patent applications. Claims 1, 3, 6-7, 10, 14-18 read upon this election.

Further, with respect to the elected group III, the Examiner required an election of a single disclosed specie of an mGluR4 receptor positive allosteric modulator. In response, the Applicants elect N-phenyl-7-(hydroxylimino)cyclo-propa[b]chromen-1a-carboxamide ("PHCCC"). This election is made without prejudice to any other non-elected mGluR4 receptor positive allosteric modulator in any related patent applications. Claims 1, 3, 6-7, 10 and 14-18 read upon this election.

Additionally, the Examiner has required an election as to whether or not the mGluR4 receptor positive allosteric modulator is administered in combination with another agent. In response, Applicant's elect the invention in which the mGluR4 receptor positive allosteric modulator is not administered in combination with another agent. Such election is made without prejudice to those aspects of the invention that employ agents claimed in related patent applications. Claims 1, 3, 10 and 14-18 read upon this election. Given this election, the Examiner's yet additional election requirement is moot and so is not discussed.


It is believed that the claims are in a condition for allowance, and a notice to that effect is respectfully requested.

If the Examiner feels that a telephone conference would be of value, he is invited to contact the undersigned counsel at the number indicated below.

The USPTO is authorized to charge Deposit Account No. 50-1943 of Fox Rothschild LLP for any charges in connection with this matter, including any fees related to extensions of time, which the USPTO may assume are requested if required.

Date: May 13, 2008

Respectfully submitted,



Gerard Bilotto
Reg. No. 51,474
Fox Rothschild LLP
100 Park Ave., Suite 1500
New York, NY 10017
Tel.: 212-878-7930
Fax: 212-692-0940
gbilotto@foxrothschild.com